Saluggia, Italy and Männedorf, Switzerland, June 23, 2017 – DiaSorin (FTSE Italy Mid Cap: DIA) and Tecan Group (SIX Swiss Exchange: TECN) announced today that they have agreed to collaborate in a development under which DiaSorin will make use of Tecan’s Fluent® Laboratory Automation Solution as its Nucleic Acid extraction platform. The new platform will... Read more
This year’s research prize awarded by Eppendorf goes to the United Kingdom Tom Baden PD., Ph.D. Heidelberg/Hamburg, June 23, 2017 In 2017, the Hamburg life science company is presenting its highly prestigious research prize for the 22nd time. The independent Eppendorf Award Jury chaired by Prof. Reinhard Jahn selected Dr. Tom Baden, Senior Lecturer in... Read more
Download PDF Read more
Basel, 23 June 2017 Presentation confirms Venclexta/Venclyxto monotherapy benefit in certain patients with high-risk chronic lymphocytic leukaemia and its potential in other hard-to-treat blood cancers First in class BCL2-specific oral inhibitor represents a potential new way of treating different blood cancers Efficacy and tolerability confirmed in high-risk patients with relapsed or refractory chronic lymphocytic leukaemia,... Read more
Basel, 23 June 2017 Roche presents new data from GALLIUM study reinforcing clinical benefit of Gazyva/Gazyvaro in people with previously untreated follicular lymphoma Longer follow-up showed sustained benefit in progression-free survival of Gazyva/Gazyvaro-based treatment over MabThera/Rituxan-based treatment regardless of chemotherapy regimens People with follicular lymphoma who received Gazyva/Gazyvaro-based treatment reported improvement in health-related quality of... Read more
Basel, 23 June 2017 FDA approves Rituxan Hycela (rituximab and hyaluronidase human) for subcutaneous injection in certain blood cancers Treatment can be administered in five to seven minutes, compared to 1.5 hours or more for intravenous Rituxan* Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) approved Rituxan... Read more
Basel, 23 June 2017 New data at EAN show Roche’s OCREVUS™ (ocrelizumab) significantly reduced multiple measures of disease progression in relapsing and primary progressive multiple sclerosis OCREVUS increased the number of patients with relapsing MS (RMS) and primary progressive MS (PPMS) who maintained No Evidence of Progression or Active Disease (NEPAD) versus Rebif (interferon beta-1a)... Read more
June 22, 2017 04:30 AM Pacific Daylight Time MILFORD, Mass.–(BUSINESS WIRE)–Waters Corporation (NYSE: WAT) today announced Dr. Flemming Ornskov, Chief Executive Officer of Shire plc, has been elected as a Director of Waters® Corporation effective today. “It is an honor to welcome Flemming Ornskov to our Board of Directors,” said Christopher J. O’Connell, Waters Corporation President... Read more
June 22, 2017 – Saluggia, Italy; Hilden, Germany, and Germantown, Maryland – DiaSorin (FTSE Italy Mid Cap: DIA) and QIAGEN (NASDAQ: QGEN; Frankfurt Stock Exchange: QIA) announced today a new collaboration to develop new tests for DiaSorin’s LIAISON family of analyzers based on a review and selection process involving QIAGEN’s assay technologies. The adoption of... Read more
Gold-standard test for latent tuberculosis infection will be covered by national health insurance Hilden, Germany, and Paris, France, June 22, 2017 – QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced that France’s Ministry of Health and Social Affairs has approved reimbursement by the national health insurance system for QIAGEN’s QuantiFERON-TB® Gold Plus (QFT-Plus®)... Read more